Cigler Tessa 4

What Happened
Tessa Cigler, a director of Atossa Therapeutics, was granted 10,000 restricted stock units (RSUs) on May 12, 2026. The grant was recorded at $0.00 (no cash exchanged at grant); each RSU represents a contingent right to one share of common stock and will vest on the first anniversary of the grant (May 12, 2027). This is an equity award (retention/compensation), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-12; transaction type: Grant/Award (code A); reported price: $0.00.
• Grant size: 10,000 RSUs; total cash paid at grant: $0.00.
• Vesting: RSUs vest on May 12, 2027 (one‑year cliff per footnote).
• Shares owned after transaction: not specified in the provided filing.
• Filing: Form 4 filed 2026-05-14 (appears timely; no late‑filing flag indicated).
• Footnote: Each RSU is a contingent right to one share of common stock (see footnote F1).

Context
RSU grants are common compensation/retention tools for directors and do not represent an immediate market buy or sell. If and when the RSUs vest, they typically convert to common shares (and may be subject to tax withholding or sale if required), at which point a separate filing may reflect the issuance or any subsequent sale.